OpenAI acquires Orchestra Bio for drug development
OpenAI: OpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
What happened
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech software startup that builds AI agents to help pharmaceutical teams manage drug development operations. Orchestra's team and technology will be integrated into Rosalind, OpenAI's AI model for life sciences research, and the Rosalind Workbench tool. The combined technology aims to help coordinate complex drug development processes, which typically take 10 to 15 years from discovery to regulatory approval.
What each outlet adds
- OpenAI ↗: The acquisition represents an effort to apply AI agents to specialized tasks such as monitoring studies, identifying how problems in one area affect others, and helping teams decide on next steps.
- TechCrunch ↗: Orchestra's AI agents help biotech companies with financial tracking and clinical trial scheduling, and the acquisition reflects a broader trend where major AI labs are building specialized software for large industries.
- SiliconANGLE ↗: Rosalind already partners with major drugmakers including Novo Nordisk and Moderna, and Orchestra's agents monitor studies, track finances, and solve clinical trial scheduling problems while humans make final decisions on important matters.
Why it matters
Drug development is extraordinarily complex and typically requires managing disconnected systems across internal departments and external partners. The acquisition reflects a trend where major AI labs are building specialized software for large industries like pharmaceuticals rather than displacing them with competing features.
Get smart on it
OpenAI has acquired Orchestra Bio, a platform that helps drug development teams coordinate the complex process of creating new medicines. The combined technology will merge Orchestra's coordination tools with Rosalind, OpenAI's AI models and tools for life sciences research, aiming to help scientists make discoveries and manage the workflow needed to bring treatments to patients faster. Drug development is extraordinarily complex and typically takes 10 to 15 years from initial discovery to regulatory approval, requiring teams to manage disconnected systems across internal departments and external partners. The acquisition represents an effort to apply AI agents to specialized tasks in drug development, such as monitoring studies, identifying how problems in one area affect others, and helping teams decide on next steps.
Relevant courses
Want to go deeper than the news? Explore live, cohort-based AI courses taught by practitioners.
Browse AI courses on MavenRelated news
Otter.ai raises $320 million from General Catalyst’s growth fund for its meeting tool
Meeting note-taking tool Otter.ai announced on Tuesday that it has raised $320 million from General Catalyst’s Customer Value Fund (CVF), which provides capital to startups without diluting equity and gets returns on the results of marketing spend. Otter.ai said that it will use these funds for enterprise growth, go-to-market strategy, international expansion, and product innovation. […]
Also reported by SiliconANGLE
AI work assistant startup Town secures unicorn status after raising $108M just weeks after launching
Town.com Inc., an artificial intelligence agent startup laser focused on getting work done by collaborating with other AI agents, revealed today that it has raised $108 million in a new funding at a $1 billion valuation. The Series B round was led by Forerunner Ventures and Menlo Ventures, and saw participation from Andreessen Horowitz, Serena […] The post AI work assistant startup Town secures unicorn status after raising $108M just weeks after launching appeared first on SiliconANGLE.
Nscale and Anthropic are reportedly in talks for yet another $45 billion compute deal
In August, Nscale and Anthropic announced a $45 billion compute deal. The two companies are reportedly discussing yet another deal of the same magnitude.
Tenstorrent hits $6.2B valuation to scale open-weight AI chips
After drawing acquisition interest earlier this year, the Nvidia challenger raised $1.5 billion to remain independent.
Anthropic’s cloud partnerships are getting messy
Anthropic is reportedly struggling to secure enough compute from cloud providers that increasingly view it as a competitor, even as its infrastructure spending balloons ahead of a planned November IPO.
Anthropic says it’s committing 5% of its shares to a ‘public benefit fund’
Anthropic said that it will commit 5% of its shares to the fund.
Also reported by The Decoder